Spiriva HandiHaler Not Linked to Risk of Stroke, Heart Attack, Death: FDA

The FDA has concluded their investigation into potential side effects of Spiriva HandiHaler, and the agency indicates that they did not find a link between the chronic pulmonary obstructive disease (COPD) inhaler and an increased risk of heart attack, stroke or death.

FDA investigators began reviewing Spiriva HandiHaler in March 2008, after preliminary data from a four year study suggested that users may face an increased risk of strokes. In a statement released Thursday, the agency indicates that they found no connection between Spiriva and stroke or heart disease.

Spiriva HandiHaler (tiotropium) is a once-daily inhaled medication used for long-term maintenance treatment of bronchospasm linked to COPD. Since it was approved by the FDA in 2004, it has grown to dominate the market for COPD inhalers and has been used by millions of Americans.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The initial study that raised concerns about Spiriva involved a combined analysis of 29 clinical trials, which found that users may face a slight increase in the risk of stroke when compared to the use of a placebo. A subsequent study in October 2008 suggested that usrs may also face an increased risk of heart attack and death, in addition to the stroke risk.

The FDA review, Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT), looked at 5,992 COPD patients and compared the health effects of Spiriva with a placebo. Both FDA officials and the FDA Pulmonary – Allergy Drugs Advisory Committee reviewed data from UPLIFT and found no correlation between use of Spiriva and heart attack, stroke or sudden death.

2 Comments

  • YvetteJuly 3, 2010 at 2:44 pm

    I was diagnosed with COPD 14 years ago I first was taking ipratropium in nebulizer for 8 years, I started with Spiriva handihaler in July 2004. my condition is getting worse, wheezin, shortness of breath, I must take ozygen several times a day, I am under a Pulmonologist care, I asked if I should stop spiriva, I must take more tests to determine outcome, I was hospitalized twice at the start of Sp[Show More]I was diagnosed with COPD 14 years ago I first was taking ipratropium in nebulizer for 8 years, I started with Spiriva handihaler in July 2004. my condition is getting worse, wheezin, shortness of breath, I must take ozygen several times a day, I am under a Pulmonologist care, I asked if I should stop spiriva, I must take more tests to determine outcome, I was hospitalized twice at the start of Spiriva.I have emphysema,How dangerous is Spiriva at this time?

  • TracyJune 8, 2010 at 3:01 pm

    What about lung cancer? My mom had been doing great-even with her COPD once she started using this product, then 1-1/2yrs into it, lung cancer...out of the blue. Sure, people could say she got it from having smoked (quit 9 yrs. earlier), but the doc's seem to think it started to grow just about the same time she started using spiriva...I find it rather interesting-the timing.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims
Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (Posted today)

Two Special Masters have been appointed to organize and manage a court-supervised mediation program that may resolve Bard hernia mesh lawsuits that do not participate in a global settlement announced last month.